Compare AHCO & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AHCO | ANAB |
|---|---|---|
| Founded | 2012 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | 2017 | 2015 |
| Metric | AHCO | ANAB |
|---|---|---|
| Price | $10.16 | $56.07 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $13.50 | ★ $71.67 |
| AVG Volume (30 Days) | ★ 1.1M | 465.0K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 91.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,244,857,000.00 | $234,603,000.00 |
| Revenue This Year | $9.00 | N/A |
| Revenue Next Year | $6.93 | $52.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 157.01 |
| 52 Week Low | $8.33 | $17.11 |
| 52 Week High | $13.43 | $73.30 |
| Indicator | AHCO | ANAB |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 48.33 |
| Support Level | $9.87 | $53.46 |
| Resistance Level | $10.21 | $57.70 |
| Average True Range (ATR) | 0.31 | 2.50 |
| MACD | 0.07 | 0.20 |
| Stochastic Oscillator | 67.98 | 60.25 |
AdaptHealth Corp is engaged in providing patient-centered, healthcare-at-home solutions including home medical equipment (HME), medical supplies, and related services. The Company operates under four reportable segments that align with its product categories: (i) Sleep Health, (ii) Respiratory Health, (iii) Diabetes Health, and (iv) Wellness at Home. The company generates majority of its revenue from the Sleep Health segment. The Sleep Health segment provides sleep therapy equipment, supplies and related services (including continuous positive airway pressure and BiLevel services) to individuals for the treatment of obstructive sleep apnea.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).